TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05585580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: 300mg d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome
Description: 135\~175mg/m2 /260mg/m2/135-175mg/m2 d1 q3w
Study: NCT05359523

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic measurements of the trapezius and rhomboid muscle and fascia
Description: B mode measurements Trapezius and rhomboid muscle thickness and fascial thickness measurement M mode measurements Abduction at 90 and 180 degrees Forward flexion at 90 and 180 degrees

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic measurements of the trapezius and rhomboid muscle and fascia
Description: B mode measurements Trapezius and rhomboid muscle thickness and fascial thickness measurement M mode measurements Abduction at 90 and 180 degrees Forward flexion at 90 and 180 degrees

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fascia injection
Description: Under ultrasound guidance, a local anesthetic and steroid mixture will be injected into the fascia between the trapezius muscle and the rhomboid muscle.
Study: NCT05842863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Dialectical Behavior Therapy (DBT) is a treatment program that helps teens reduce suicidal and self-harm behaviors by teaching them coping skills for managing negative emotions. DBT includes weekly individual therapy, weekly multifamily skills group, and 24/7 telephone-based skills coaching from the therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical Behavior Therapy
Description: Dialectical Behavior Therapy (DBT) is a treatment program that helps teens reduce suicidal and self-harm behaviors by teaching them coping skills for managing negative emotions. DBT includes weekly individual therapy, weekly multifamily skills group, and 24/7 telephone-based skills coaching from the therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia (CBTI) is a type of counseling that helps people improve sleep by changing their sleep behaviors and thinking about sleep. In CBTI, people learn about sleep regulation, factors that influence quantity and quality of sleep, and specific techniques to optimize sleep. In this study, CBTI will be delivered using a self-guided online program called Firefly.
Study: NCT04700228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
Study: NCT06487312

Intervention type: DEVICE
Intervention: Test equipment: Name: Remote automatic ultrasound diagnostic system (Wuhan Cooper Technology Co., Ltd.) Model: CORUS-A30
Description: A clinical trial to evaluate the effectiveness and safety of a remote automated ultrasound diagnostic system for automated ultrasound examination using a remote automated ultrasound diagnostic system (model: CORUS-A30, Wuhan Cooper Technology Co., Ltd., China).
Study: NCT04700228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
Study: NCT05275127

Intervention type: OTHER
Intervention: changes of gingival crevicular fluid miRNA
Description: Evaluation of changes of gingival crevicular fluid miRNA after periodontal treatment

Intervention type: OTHER
Intervention: changes of gingival crevicular fluid miRNA
Description: Evaluation of changes of gingival crevicular fluid miRNA after periodontal treatment
Study: NCT05849740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab and corticosteroid treatment
Description: Daratumumab and corticosteroid treatment
Study: NCT05213689

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational comic book
Description: An educational comic book was developed with qualitative data collected from an earlier study phase involving focus groups with youth from Bidi Bidi. The comic book is focused on HIV testing information and decision making as it follows the story of youth in Bidi Bidi who are seeking out HIV testing. Each youth in the appropriate arm with receive a copy of the comic book and together with 5-10 other youth will meet with a PN to read through and discuss the comic book. The comic will also include blank pages so that the youth can participate in the dialogue of the comic book. The comic will be available in English, Bari and Juba Arabic.
Study: NCT05346341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive techniques
Description: All patient will be treated under general anaesthesia An appropriate gland-preserving minimally-invasive surgical procedure will be performed for all patients according to the nature and extent of the disease for either submandibular or parotid ducts.~Minimally invasive techniques for ductal salivary gland pathologies include:~1. Sialolithotomy through a simple cutdown~2. Sialendoscopy~3. Transoral microscopic-assisted sialolithotomy.
Study: NCT06099418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.16
Description: Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49.~A total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.16
Description: Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49.~A total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection [Tecentriq]
Description: Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.
Study: NCT06341413

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SmartSleep device
Description: Device worn during sleep

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartSleep device
Description: Device worn during sleep
Study: NCT06077292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 15% THC Potency Reduction
Description: Participants will be incentivized to use THC products that are at least 15% less potent than baseline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 35% THC Potency Reduction
Description: Participants will be incentivized to use THC products that are at least 35% less potent than baseline
Study: NCT05872672

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Program
Description: Participants will complete the Headspace Health Sleep Program, which is an 18 day program based on CBTi, and includes the following intervention components: 1) a sleep diary to monitor sleep and associated factors; 2) cognitive interventions to address maladaptive thoughts related to sleep; 3) behavioral interventions to address maladaptive behaviors related to sleep (e.g., sleep hygiene, stimulus control, and sleep restriction); 4) de-arousal techniques (e.g., mindfulness, breathing, and muscle relaxation exercises).

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist
Description: Participants will continue their regular sleep routines for an 18 day period and will not be assigned to an intervention.
Study: NCT04669483

Intervention type: OTHER
Intervention: evidence-based informed consent form
Description: Evidence-based informed consent forms for total knee arthroplasty and related anesthesia procedures will be developed. The design of the evidence-based informed consent forms will be guided by an existing guideline on how to present evidence-based health information (guideline evidence-based health information) and nocebo research. The information will be presented in plain language. Benefits and harms of the procedures will be presented in absolute risk formats and in comparison with other interventions or placebo. Verbal presentations of risks lead to overestimations of risks and therefore, will not be applied exclusively. Gain and loss framing will be combined. To visualize important aspects, pictograms will be used. Information on uncertainty, missing or low quality evidence will be provided.
Study: NCT04843423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: At the screening visit, those who are eligible will enter an open-label trial with cariprazine in doses ranging from 1.5mg to 3 mg. The study will begin with a single week of cariprazine 1.5 mg oral tablets. After the first week the participants' dosage may be increased up to a maximum of 3 mg daily. This dose will remain fixed after 4 weeks of treatment until week 8, at which time the medication will be discontinued.~Because the drug is not yet available to market in Canada, participants will be dispensed the drug in appropriately labelled 7-day tablet containers with the appropriate dose, including 3 additional tablets to account for scheduling conflicts. Participants will be instructed to return the tablet containers at each Study Visit in order to assess drug compliance. They will then be newly dispensed the appropriate quantity according to their next scheduled study visit.
Study: NCT05800795

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er: YAG laser
Description: surface treatment with Er: YAG laser for heating abutments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plasma spray
Description: surface treatment with plasma spray for heating abutments
Study: NCT06513312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Injection
Description: Administered subcutaneously
Study: NCT05053789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrimera
Description: A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylo-Vision
Description: Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).
Study: NCT05213689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational comic book
Description: An educational comic book was developed with qualitative data collected from an earlier study phase involving focus groups with youth from Bidi Bidi. The comic book is focused on HIV testing information and decision making as it follows the story of youth in Bidi Bidi who are seeking out HIV testing. Each youth in the appropriate arm with receive a copy of the comic book and together with 5-10 other youth will meet with a PN to read through and discuss the comic book. The comic will also include blank pages so that the youth can participate in the dialogue of the comic book. The comic will be available in English, Bari and Juba Arabic.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV Self-testing
Description: Participants will receive HIVST kits so that they can perform their HIV testing.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV Self-testing
Description: Participants will receive HIVST kits so that they can perform their HIV testing.
Study: NCT06513312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Injection
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Tablet
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Tablet
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Description: Administered orally
Study: NCT05472051

Intervention type: OTHER
Intervention: Community-based healthcare offer provided by an the ARCAD Santé PLUS NGO and integrated into the activities of the ADDAD NGO
Description: In the framework of the current activities of the ARCAD Santé PLUS a team formed by a doctor, a nurse and laboratory assistant will provide prevention and medical activities during the community-based activities organized by the housekeepers ADDAD NGO. The medical consultation will propose:~* HIV screening, including pre- and post- counseling~* Hepatitis B and hepatitis C screening, including pré- and post- counseling. The HBV vaccine will be proposed to housekeepers with negative results to both HBV and HCV testing~* Tuberculosis screening will be proposed to housekeepers with symptoms suggesting the possibility of TB~* For housekeepers sexually active, the medical team will propose a gynecological test in order to screen for genital infections. Furthermore, a pregnancy test will be proposed.~Medicines for current diseases (headache, diarrhea, etc. will be provided by the medical staff).
Study: NCT05428969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexmarilimab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexmarilimab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexmarilimab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: As per label, subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: As per label, subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: As per label, subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral
Study: NCT05317364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol 0.01% Vag Cream
Description: 1g estradiol vaginal cream 0.01% or placebo will be administered nightly for 2 weeks then twice weekly to complete 6 months therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal cream
Description: Placebo cream
Study: NCT05920655

Intervention type: DIAGNOSTIC_TEST
Intervention: Optic coherence tomography
Description: Eye examination of patients with optic coherence tomography test by an ophthalmologist

Intervention type: DIAGNOSTIC_TEST
Intervention: Optic coherence tomography
Description: Eye examination of patients with optic coherence tomography test by an ophthalmologist

Intervention type: DIAGNOSTIC_TEST
Intervention: Optic coherence tomography
Description: Eye examination of patients with optic coherence tomography test by an ophthalmologist
Study: NCT05086640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lemon foot to prevent blister
Description: The investigators make the hypothesis that the local application of Lemon allows a reduction of the number of blisters on ultra-trail.
Study: NCT05224232

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid socket
Description: During a period of 4 weeks, patients will live in their usual environment with their usual rigid socket
Study: NCT05477537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity program
Description: subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks) Adapted Physical Activity program, including psychoeducation on both problematic physical activity and consequences in terms of physical activity good practice leads to a better outcome among persons suffering from anorexia nervosa.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual group
Description: Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual)
Study: NCT04983836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anesthesia technique
Description: locoregional anaesthesia allowing analgesia of the hemi-thorax by ultrasound guided single injection of naropeine 5mg/ml

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Paravertebral anesthesia technique
Description: Ultrasound guided single injection of of naropeine 5mg/ml dose into the paravertebral space next to the thoracic spine
Study: NCT04728789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag 20 MG
Description: Avatrombopag 20mg/week to 60mg/day, starting at 20mg/day and increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
Study: NCT06036615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Patients that will be randomly assigned to this group will be invited to attend up to 72 exercise sessions (3 sessions per week) for 24 weeks (6 months) following a combined aerobic, strengthening and mobility-flexibility exercise program. After the exercise intervention, the will follow a 3-month de-training period, continuing their normal physical activity.
Study: NCT04533347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafenoquine Oral Tablet
Description: Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
Study: NCT05840393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge training based on Roy adaptation model
Description: The Roy Adaptation Model consists of four main areas of adaptation. In this study, the content of the discharge education given within the scope of the adaptation areas of the Roy Adaptation Model will be continued with information such as home nutrition process, pain, anxiety, fear, stress and coping methods, addressing changing roles and responsibilities, communication, problem solving and utilizing social support. A booklet will be prepared to increase the effectiveness of discharge training based on the Roy Adaptation Model and the booklet will be used as a guide in the training program.
Study: NCT05699252

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The CBT intervention will be used to help participants learn about the role of cognitions (particularly pain catastrophizing), pain beliefs (including perceived control), and maladaptive or unhelpful coping behaviors in chronic pain. This technique will help participants: (1) identify and change or restructure unhelpful or negative thinking about pain; (2) utilize positive coping strategies including positive coping self-statements; relaxation techniques; behavioral activation (including setting goals for activation), activity pacing and scheduling; and (3) cope with pain flare-ups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotic Cognitive Therapy (HYP-CT)
Description: The HYP-CT intervention will be used to help participants learn about the role of hypnosis to reduce pain, increase comfort and well-being, and to instill and reinforce healthy, adaptive cognitions. This technique will help participants to use their ability to enter a state of focused attention to then increase their acceptance of new adaptive ideas about pain provided both by (1) clinicians during sessions and on audio recordings, as well as (2) the participants themselves during self-hypnosis practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: The MBCT intervention will be used to help participants learn about the role of MBCT in training the mind to respond more adaptively to pain. This technique will help participants: (1) apply the skills they learn not only to pain but also to the problems pain causes for them, including sleep disturbance, depressed mood, stress, and other problems; (2) build on their strengths and their innate ability to focus their attention at will, and to use this ability to mindfully perceive experience in a non-judgmental, non-reactive way; and (3) notice their moment-to-moment experience and to shift their relationship to this experience. With enhanced mindful awareness comes the opportunity to then mindfully choose how to respond to the pain in a way that reduces stress and is most helpful or adaptive.